Since we recently found an interaction between RPS4X and YB-1 proteins [15] that may affect clinical outcomes of patients, we determined the levels of expression of these proteins by immunohistochemistry in 192 clinical samples from women with ovarian cancer (Table 1). This evidence concerns the gene RPS4X and ovarian cancer.